EA200000461A1 - Компоненты, улучшающие кожную проницаемость - Google Patents

Компоненты, улучшающие кожную проницаемость

Info

Publication number
EA200000461A1
EA200000461A1 EA200000461A EA200000461A EA200000461A1 EA 200000461 A1 EA200000461 A1 EA 200000461A1 EA 200000461 A EA200000461 A EA 200000461A EA 200000461 A EA200000461 A EA 200000461A EA 200000461 A1 EA200000461 A1 EA 200000461A1
Authority
EA
Eurasian Patent Office
Prior art keywords
penetration
macrolide
derivative
biologically active
macrocyclic lactone
Prior art date
Application number
EA200000461A
Other languages
English (en)
Other versions
EA003616B1 (ru
Inventor
Энтони Дэвид Ормерод
Артур Винфилд
Original Assignee
Абердин Юнивёсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Абердин Юнивёсити filed Critical Абердин Юнивёсити
Publication of EA200000461A1 publication Critical patent/EA200000461A1/ru
Publication of EA003616B1 publication Critical patent/EA003616B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Настоящее изобретение относится к составу для локального нанесения для лечения дерматологического заболевания, который содержит макроциклический лактоновый антибиотик, иммунодепрессивный макролид или их биологически активный аналог, производное или пролекарство на их основе, отличающемуся тем, что он дополнительно содержит модулятор проницаемости, при этом модулятор проницаемости и макроциклический лактоновый антибиотик или макролид или биологически активный аналог, их производное или пролекарство на их основе присутствуют в таких относительных количествах, что при нанесении на кожу терапевтической дозы оказывается минимальное воздействие на общую систему организма. В качестве иммунодепрессивного макролида может использоваться сиролим.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000461A 1997-11-07 1998-11-05 Компоненты, улучшающие кожную проницаемость EA003616B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723669.9A GB9723669D0 (en) 1997-11-07 1997-11-07 Skin penetration enhancing components
PCT/GB1998/003317 WO1999024036A1 (en) 1997-11-07 1998-11-05 Skin penetration enhancing components

Publications (2)

Publication Number Publication Date
EA200000461A1 true EA200000461A1 (ru) 2000-10-30
EA003616B1 EA003616B1 (ru) 2003-08-28

Family

ID=10821813

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000461A EA003616B1 (ru) 1997-11-07 1998-11-05 Компоненты, улучшающие кожную проницаемость

Country Status (33)

Country Link
US (2) US6958153B1 (ru)
EP (2) EP1632231A3 (ru)
JP (1) JP2001522801A (ru)
KR (1) KR20010031741A (ru)
CN (1) CN1115148C (ru)
AR (1) AR014011A1 (ru)
AT (1) ATE332134T1 (ru)
AU (1) AU759326B2 (ru)
BG (1) BG104370A (ru)
BR (1) BR9815264A (ru)
CA (1) CA2309159C (ru)
CY (1) CY1105243T1 (ru)
DE (1) DE69835163T2 (ru)
DK (1) DK1028727T3 (ru)
EA (1) EA003616B1 (ru)
EE (1) EE04390B1 (ru)
ES (1) ES2268795T3 (ru)
GB (1) GB9723669D0 (ru)
GE (2) GEP20032884B (ru)
HR (1) HRP20000233A2 (ru)
HU (1) HUP0003675A3 (ru)
ID (1) ID24662A (ru)
IL (1) IL135978A0 (ru)
NO (1) NO20002078L (ru)
NZ (3) NZ530752A (ru)
PL (1) PL340710A1 (ru)
PT (1) PT1028727E (ru)
SK (1) SK6622000A3 (ru)
TR (1) TR200001238T2 (ru)
TW (1) TW557218B (ru)
UA (1) UA73274C2 (ru)
WO (1) WO1999024036A1 (ru)
ZA (1) ZA9810111B (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
WO2001066117A1 (en) * 2000-03-09 2001-09-13 Ian Andrew Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
CN1617709A (zh) * 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 克拉霉素的稳定局部制剂
KR20040106547A (ko) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 비타민-마이토마이신 공액체
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20070154966A1 (en) * 2003-12-29 2007-07-05 Ronit Sagi-Eisenberg Assay for the detection of rapamycin and rapamycin analogs
US8288557B2 (en) * 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
MX2007002961A (es) * 2004-09-16 2008-03-13 Bayer Healthcare Ag Fromulaciones aplicables dermicamente para el tratamiento de enfermedades cutaneas en animales.
EP1858482B1 (en) 2005-03-10 2014-04-23 3M Innovative Properties Company Methods of reducing microbial contamination
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2481427A1 (en) * 2007-03-14 2012-08-01 Endocyte, Inc. Folate-Tubulysin conjugates
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US7919250B2 (en) 2007-07-31 2011-04-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
EP3162380A1 (en) * 2014-06-26 2017-05-03 Osaka University Antiperspirant agent
EP3352755A4 (en) 2015-09-24 2019-04-03 Drexel University Novel Compositions and Methods for the Treatment and Prevention of Skin Diseases
FR3050206B1 (fr) 2016-04-15 2018-05-11 Engie Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
MX2021010058A (es) 2019-02-20 2021-11-12 Ai Therapeutics Inc Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
EP4114357A4 (en) 2020-03-02 2024-05-01 Shanghai Aucta Pharmaceuticals Co., Ltd. TOPICAL FORMULATIONS WITH MTOR INHIBITORS
FR3112537B1 (fr) 2020-07-14 2023-03-31 Engie Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31769A (en) * 1861-03-26 Water-elevator
US3376646A (en) * 1967-03-30 1968-04-09 Herman E. Radke Template tracer
US4335115A (en) 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
DK0582239T3 (da) * 1992-08-04 1999-12-06 Rhone Poulenc Rorer Gmbh Farmaceutisk og/eller kosmetisk formulering
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi) 1993-02-01 1994-03-10 Pauli Groenberg Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
JPH08133979A (ja) 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
KR100434682B1 (ko) * 1994-10-26 2004-08-18 노바티스 아게 약학조성물
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use

Also Published As

Publication number Publication date
HRP20000233A2 (en) 2001-02-28
UA73274C2 (en) 2005-07-15
HUP0003675A2 (hu) 2001-04-28
KR20010031741A (ko) 2001-04-16
PT1028727E (pt) 2006-11-30
JP2001522801A (ja) 2001-11-20
ID24662A (id) 2000-07-27
NO20002078L (no) 2000-07-06
GEP20043171B (en) 2004-02-25
IL135978A0 (en) 2001-05-20
EA003616B1 (ru) 2003-08-28
DE69835163D1 (de) 2006-08-17
NO20002078D0 (no) 2000-04-19
EP1028727A1 (en) 2000-08-23
US6958153B1 (en) 2005-10-25
ES2268795T3 (es) 2007-03-16
EE200000279A (et) 2001-10-15
SK6622000A3 (en) 2001-01-18
CY1105243T1 (el) 2010-03-03
ZA9810111B (en) 1999-05-07
BG104370A (en) 2000-12-29
CN1115148C (zh) 2003-07-23
AU1040899A (en) 1999-05-31
GB9723669D0 (en) 1998-01-07
EP1632231A3 (en) 2008-01-23
NZ504076A (en) 2002-12-20
NZ530752A (en) 2005-05-27
HUP0003675A3 (en) 2001-05-28
CN1278173A (zh) 2000-12-27
DE69835163T2 (de) 2007-05-31
NZ520449A (en) 2004-04-30
DK1028727T3 (da) 2006-10-23
PL340710A1 (en) 2001-02-26
WO1999024036A1 (en) 1999-05-20
US20050239724A1 (en) 2005-10-27
TR200001238T2 (tr) 2001-01-22
CA2309159A1 (en) 1999-05-20
EP1632231A2 (en) 2006-03-08
AU759326B2 (en) 2003-04-10
EE04390B1 (et) 2004-12-15
ATE332134T1 (de) 2006-07-15
TW557218B (en) 2003-10-11
BR9815264A (pt) 2001-08-14
GEP20032884B (en) 2003-02-25
AR014011A1 (es) 2001-01-31
CA2309159C (en) 2009-03-17
EP1028727B1 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
EA200000461A1 (ru) Компоненты, улучшающие кожную проницаемость
EA199900553A1 (ru) Чрескожная терапевтическая система
BR9711447A (pt) Uso de glp-1 an logos no tratamento de enfarte de mioc rdio
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
FI963219A (fi) Mykofenolihapon 4-aminojohdannaiset, joilla on immunosuppressanttiaktiivisuutta
DK0806941T3 (da) Liposomalt antibakterielt præparat med lav fasthed
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
UA29466C2 (ru) Фармацевтическая композиция с антиопухолевой активностью
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ATE227973T1 (de) Kosmetische, dermatologische und pharmazeutische anwendung eines terminalia catappa pflanzenextrakts
EA199800589A1 (ru) Применение экстрактов гинкго двудольного для получения фармацевтичиских композиций и способ косметической обработки с его использованием
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
ATE260559T1 (de) Sordarinderivate
ATE331730T1 (de) Neue depsipeptid-verbindung
AU3401093A (en) Therapeutic agent for threatened abortion
FI963222A0 (fi) 6-substituoitu 4-amino-mykofenolihappo ja sen johdannaiset, joilla on immunosuppressiivista aktiivisuutta
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
BR9714945A (pt) Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos
DE69813833T2 (de) 4-cyano-4-deformylsordarizin-derivate
ATE241979T1 (de) 4-cyano-4-deformylsordarinderivate
ATE60578T1 (de) Prostacyclinanalog, dieses als aktives bestandteil enthaltendes, den blutumlauf verbesserndes mittel und gegen magengeschwuere wirkendes mittel.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU